Further, we show that knockdown of SF3B1 or treatment with the SF3B1 inhibitor Pladienolide-B reduces cell viability, migration, and invasion of endometrial cancer cells in vitro and endometrial tumor cell growth in vivo. Here, SF3B1 is linked to endometrial cancer.